Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Diabetes mellitus (DM) is one of the most prevalent metabolic disorders. In order to replace the function of the destroyed pancreatic beta cells in diabetes, islet transplantation is the most widely practiced treatment. However, it has several limitations. As an alternative approach, human pluripotent stem cells (hPSCs) can provide an unlimited source of pancreatic cells that have the ability to secrete insulin in response to a high blood glucose level. However, the determination of the appropriate pancreatic lineage candidate for the purpose of cell therapy for the treatment of diabetes is still debated. While hPSC-derived beta cells are perceived as the ultimate candidate, their efficiency needs further improvement in order to obtain a sufficient number of glucose responsive beta cells for transplantation therapy. On the other hand, hPSC-derived pancreatic progenitors can be efficiently generated in vitro and can further mature into glucose responsive beta cells in vivo after transplantation. Herein, we discuss the advantages and predicted challenges associated with the use of each of the two pancreatic lineage products for diabetes cell therapy. Furthermore, we address the co-generation of functionally relevant islet cell subpopulations and structural properties contributing to the glucose responsiveness of beta cells, as well as the available encapsulation technology for these cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Generation of Functional Human Pancreatic β Cells In Vitro
Pagliuca, F. W., Millman, J. R., Gürtler, M., Segel, M., Van Dervort, A., Ryu, J. H., Peterson, Q. P., Greiner, D., & Melton, D. A. (2014) · Cell · doi:10.1016/j.cell.2014.09.040 · Cited by 2,025
Kroon, E., Martinson, L. A., Kadoya, K., Bang, A. G., Kelly, O. G., Eliazer, S., Young, H., Richardson, M., Smart, N. G., Cunningham, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1393 · Cited by 1,843 · cited 1×
“While the viability, and hence, developmental capacity of hPSC‐derived pancreatic progenitor, immune‐protected during the longer maturation period in vivo has been demonstrated in rodents [9,30,31], it is yet to be determined in humans.”
BackgroundReversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells
Rezania, A., Bruin, J. E., Arora, P., Rubin, A., Batushansky, I., Asadi, A., O'Dwyer, S., Quiskamp, N., Mojibian, M., Albrecht, T., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3033 · Cited by 1,575
Mechanisms of Pancreatic β-Cell Death in Type 1 and Type 2 Diabetes
Cnop, M., Welsh, N., Jonas, J.-C., Jörns, A., Lenzen, S., & Eizirik, D. L. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s97 · Cited by 1,491 · cited 1×
“T1D is characterized by beta cell destruction as a result of autoimmune defect, while T2D pathogenesis involves the development of insulin resistance in the insulin‐target tissues followed by beta cell dysfunction due to a combination of genetic and environmental factors [1].”
BackgroundThe unique cytoarchitecture of human pancreatic islets has implications for islet cell function
Cabrera, O., Berman, D. M., Kenyon, N. S., Ricordi, C., Berggren, P.-O., & Caicedo, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510790103 · Cited by 1,312
Conversion of adult pancreatic α-cells to β-cells after extreme β-cell loss
Thorel, F., Népote, V., Avril, I., Kohno, K., Desgraz, R., Chera, S., & Herrera, P. L. (2010) · Nature · doi:10.1038/nature08894 · Cited by 1,136 · cited 1×
“In addition, pancreatic exocrine tissue and other pancreatic endocrine cell types have also been shown to transdifferentiate to INS+ cells [43,45-47].”
BackgroundControlled induction of human pancreatic progenitors produces functional beta‐like cells in vitro
Russ, H. A., Parent, A. V., Ringler, J. J., Hennings, T. G., Nair, G. G., Shveygert, M., Guo, T., Puri, S., Haataja, L., Cirulli, V., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201591058 · Cited by 591
Rezania, A., Bruin, J. E., Riedel, M. J., Mojibian, M., Asadi, A., Xu, J., Gauvin, R., Narayan, K., Karanu, F., O’Neil, J. J., et al. (2012) · Diabetes · doi:10.2337/db11-1711 · Cited by 582 · cited 3×
“However, it is worth noting that pancreatic progenitors transplanted subcutaneously or under kidney capsules have, nevertheless, resulted in their differentiation into functional beta cells [15,30], despite not being exposed to a ‘pancreatic’ microenvironment.”
BackgroundTargeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility
Xu, H., Wang, B., Ono, M., Kagita, A., Fujii, K., Sasakawa, N., Ueda, T., Gee, P., Nishikawa, M., Nomura, M., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.02.005 · Cited by 581 · cited 1×
“Recently, it was shown that the deletion of either beta‐2‐microglobulin, that abolishes the expression of any class I HLA protein or simply HLA‐A and HLA‐B, but only one allele of HLA‐C allowed the hPSC graft to evade T cell attack [109].”
BackgroundCharting cellular identity during human in vitro β-cell differentiation
Veres, A., Faust, A. L., Bushnell, H. L., Engquist, E. N., Kenty, J. H.-R., Harb, G., Poh, Y.-C., Sintov, E., Gürtler, M., Pagliuca, F. W., et al. (2019) · Nature · doi:10.1038/s41586-019-1168-5 · Cited by 552
Vegas, A. J., Veiseh, O., Doloff, J. C., Ma, M., Tam, H. H., Bratlie, K., Li, J., Bader, A. R., Langan, E., Olejnik, K., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3462 · Cited by 551
Clinical implications of a molecular genetic classification of monogenic β-cell diabetes
Murphy, R., Ellard, S., & Hattersley, A. T. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0778 · Cited by 502 · cited 1×
“Monogenic diabetes (MD), a rare form of the disease, is characterized by genetic mutations in a specific gene involved in pancreatic development and/or beta cell function [2].”
BackgroundNair, G. G., Liu, J. S., Russ, H. A., Tran, S., Saxton, M. S., Chen, R., Juang, C., Li, M.-L., Nguyen, V. Q., Giacometti, S., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0271-4 · Cited by 472 · cited 5×
“However, those beta cells express low levels of maturity markers UCN3, MAFA, and G6PC2 in comparision to adult human beta cells [18].”
BackgroundInfluentialBeta cell hubs dictate pancreatic islet responses to glucose
Johnston, N. R., Mitchell, R. K., Haythorne, E., Pessoa, M. P., Semplici, F., Ferrer, J., Piemonti, L., Marchetti, P., Bugliani, M., Bosco, D., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.020 · Cited by 454 · cited 3×
“Beta cell hubs were shown to possess pacemaker properties for initiation of electrical stimulation in an intact islet [60,84].”
BackgroundRavier, M. A., Güldenagel, M., Charollais, A., Gjinovci, A., Caille, D., Söhl, G., Wollheim, C. B., Willecke, K., Henquin, J.-C., & Meda, P. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1798 · Cited by 360
Differentiated human stem cells resemble fetal, not adult, β cells
Hrvatin, S., O’Donnell, C. W., Deng, F., Millman, J. R., Pagliuca, F. W., DiIorio, P., Rezania, A., Gifford, D. K., & Melton, D. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400709111 · Cited by 302 · cited 2×
“Therefore, their use as an encapsulant for hPSC‐derived beta cells, without a protective retrievable device could raise concerns as hPSC‐derived beta cells have not yet been proven to be completely identical to pancreatic adult islets [27] and require their retrieval periodically to assess their viability, function, a…”
BackgroundOptimal implantation site for pancreatic islet transplantation
Merani, S., Toso, C., Emamaullee, J., & Shapiro, A. M. J. (2008) · British Journal of Surgery · doi:10.1002/bjs.6391 · Cited by 257 · cited 1×
“In the case of no encapsulation, the selection of a transplantation site that has a higher oxygen pressure or is highly vascularized is rather preferable [78].”
BackgroundUrocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion
van der Meulen, T., Donaldson, C. J., Cáceres, E., Hunter, A. E., Cowing-Zitron, C., Pound, L. D., Adams, M. W., Zembrzycki, A., Grove, K. L., & Huising, M. O. (2015) · Nature Medicine · doi:10.1038/nm.3872 · Cited by 256 · cited 1×
“On the other hand, SST secreted from the delta cells of the islet inhibits insulin secretion [69].”
BackgroundAgulnick, A. D., Ambruzs, D. M., Moorman, M. A., Bhoumik, A., Cesario, R. M., Payne, J. K., Kelly, J. R., Haakmeester, C., Srijemac, R., Wilson, A. Z., et al. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0079 · Cited by 248
Bruin, J. E., Rezania, A., Xu, J., Narayan, K., Fox, J. K., O’Neil, J. J., & Kieffer, T. J. (2013) · Diabetologia · doi:10.1007/s00125-013-2955-4 · Cited by 216
Speier, S., Gjinovci, A., Charollais, A., Meda, P., & Rupnik, M. (2007) · Diabetes · doi:10.2337/db06-0232 · Cited by 166
Benninger, R. K. P., Head, W. S., Zhang, M., Satin, L. S., & Piston, D. W. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2011.218909 · Cited by 165
Linking a cell-division gene and a suicide gene to define and improve cell therapy safety
Liang, Q., Monetti, C., Shutova, M. V., Neely, E. J., Hacibekiroglu, S., Yang, H., Kim, C., Zhang, P., Li, C., Nagy, K., et al. (2018) · Nature · doi:10.1038/s41586-018-0733-7 · Cited by 158 · cited 2×
“Other genes, such as herpes simplex virus thymidine kinase (HSV‐tk), introduced with the promoter of a variety of markers characterizing pluripotency, such as Telomerase (hTERT) [113], cell cycle regulator CDK1 [114], as well as microRNA expressed in undifferentiated cells such as Let7 [115], have also shown encouragi…”
ResultAlagpulinsa, D. A., Cao, J. J. L., Driscoll, R. K., Sîrbulescu, R. F., Penson, M. F. E., Sremac, M., Engquist, E. N., Brauns, T. A., Markmann, J. F., Melton, D. A., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15308 · Cited by 130 · cited 1×
“CXCL12 coating was recently shown to prolong the viability of hPSC‐ derived beta cells in immune‐competent mice without requiring immunosuppression by preventing fibrotic overgrowth [99].”
BackgroundKirk, K., Hao, E., Lahmy, R., & Itkin-Ansari, P. (2014) · Stem Cell Research · doi:10.1016/j.scr.2014.03.003 · Cited by 96 · cited 1×
“In addition, the device has allowed maturation of hPSC-derived pancreatic lineages into pancreatic beta cells in animal models and proved competent at controlling hyperglycemia [9,31,33,101-105].”
BackgroundLong-Term Culture of Self-renewing Pancreatic Progenitors Derived from Human Pluripotent Stem Cells
Trott, J., Tan, E. K., Ong, S., Titmarsh, D. M., Denil, S. L. I. J., Giam, M., Wong, C. K., Wang, J., Shboul, M., Eio, M., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.05.019 · Cited by 77 · cited 4×
“1 expression in PDX1+/SOX9+ expanded cells, they were nevertheless able to generate C‐peptide expressing cells upon employing appropriate differentiation protocol, as well as ductal cells [38,39].”
BackgroundInfluentialKonagaya, S., & Iwata, H. (2019) · Scientific Reports · doi:10.1038/s41598-018-36606-7 · Cited by 30
Cited by
Ramzy, A., Thompson, D. M., Ward-Hartstonge, K. A., Ivison, S., Cook, L., Garcia, R. V., Loyal, J., Kim, P. T. W., Warnock, G. L., Levings, M. K., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.10.003 · Cited by 342
Current status of stem cell therapy for type 1 diabetes: a critique and a prospective consideration
Ghoneim, M. A., Gabr, M. M., El-Halawani, S. M., & Refaie, A. F. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03636-0 · Cited by 49
Metadata
- Authors
- Memon, B., & Abdelalim, E. M.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-01-23
- Volume
- 9
- Issue
- 2
- Pages
- 283
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W3000048504
- Cited by
- 100
- References
- 27
- FWCI
- 13.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.